Seelos Therapeutics Announces Positive Topline Data from the Open-Label Study of SLS-002 (Intranasal Racemic Ketamine) - BioSpace

Submitted by Anonymous (not verified) on Mon, 05/17/2021 - 10:59

Seelos Therapeutics Announces Positive Topline Data from the Open-Label Study of SLS-002 (Intranasal Racemic Ketamine)  BioSpace